A rare clinical presentation of Ebstein-Barr virus  by Öncel, Çagatay
211
LE
T
T
ER
 
T
O
 E
D
IT
O
R
A rare clinical presentation of Ebstein-Barr virus
Author
Çagatay Öncel
MD - Department of 
Neurology Pamukkale 
- University Faculty of 
Medicine Denizli-Turkey.
Submitted on: 01/21/2009
Approved on: 05/31/2009
Correspondence to: 
Hastane cad. No. 26
Denizli – Turkey
Phone: 0090 258 2612673
Fax: 0090 258 2423512
E-mail: cagatayoncel@
yahoo.com
ABSTRACT
In this letter we report a case of Guillain-Barré syndrome associated with infectious mononucleosis. 
A 20-year-old woman presented to our hospital with weakness of legs and arms. She had felt weak-
ness in her legs for three days and in arms for one day. She had one week history of pharyingitis, 
muscle pain, and fever. Serological data confi rmed infectious mononucleosis. Electrophysiological 
fi ndings and cerebrospinal ﬂ uid examinations confi rmed Guillain-Barré syndrome. She was treated 
with immunoglobulin, methylprednisolone and acyclovir. Paresis improved fi ve days after the end 
of immunoglobulin therapy. Ebstein-Barr virus infection and infectious mononucleosis must be 
considered among patients with Guillain-Barré syndrome.
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TO THE EDITOR
A 20-year old woman admitted to our hospi-
tal reporting weakness, which had begun three 
days ago at her legs. She also reported weakness 
at her arms, which started one day ago. She had 
one week history of pharyingitis, muscle pain, 
and fever around 38° C.
Neurological examination revealed pare-
sis of (Medical Research Council) MRC grade 
3-4, with absent deep tendon reﬂ exes. Cer-
ebrospinal ﬂ uid revealed increased protein 
80 mg/dL (15-45 mg/dL) with 10/mm3 leu-
kocytes and a glucose level of 52 mg/dL 
(40-70 mg/dL). Electrodiagnostic studies were 
performed on days 4 and 11 of weakness. Ab-
sent F waves and normal motor latencies were 
observed. Concurrent neurological fi ndings, 
results of cerebrospinal ﬂ uid analysis, and 
nerve conduction studies were compatible 
with axonal form of Guillain-Barré syndrome 
(GBS). Bacterial cultures were negative. Com-
plete blood count, serum electrolytes, and 
renal function tests were normal. Aspartate 
transaminase was 96 IU/L (5-35 IU/L) and 
alanine transaminase 104 IU/L (0-55 IU/L). 
Urinary excretion of porphyrins was normal. 
Serologic tests for HIV, VDRL, CMV, HSV, 
hepatitis A, hepatitis B, hepatitis C, b Borre-
lia, and Brucella were all negative. VCA-IgM 
and VCA IgG were positive. Anti EBNA IgM 
was negative, Anti EA-D IgG was positive. 
Also serological data confi rmed infectious 
mononucleosis (IM). She was treated for GBS 
and IM with immunoglobulin IV 0.4 g/kg/d 
for 5 days, methylprednisolone IV 1 g for 3 
days, and acyclovir IV 750 mg q8h for 2 weeks. 
Paresis improved 5 days after the end of im-
munoglobulin therapy, but facial paresis did 
not recovered. 
Ebstein-Barr virus (EBV) infects more than 
98% of world’s adult population, primary EBV 
infection occurs usually during childhood. EBV 
enters the body by infecting epithelial cells in the 
oropharynx. IM is a primary clinical syndrome of 
EBV, which occurs with fever, pharyingitis, fatigue, 
lymphadenopathy, splenomegaly, and elevated 
liver functional tests.1 Most IM is a self limited 
disease, but it could cause many systemic com-
plications, such as cardiac, renal, hepatic, hema-
tological, immunological, respiratory, and neuro-
logical. Neurological complications account for 
2-5% of patients.2,3 The most seen neurological 
complications of IM are encephalitis, meningitis, 
GBS with the involvement of cranial nerves, cer-
ebellitis, myelitis, and cranial neuropathies. As we 
know, the clinical picture of GBS is usually a gen-
eralized polyradiculoneuropathy affecting limbs 
proximally and distally and commonly spreading 
to involve facial and other cranial nerves.2,3 
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Although the effect of methylprednisolone and acyclovir 
treatment in IM and GBS has not been investigated in ran-
domized studies, patients treated with corticosteroids and 
acyclovir seem to be improved.2,4 In our case, paresis im-
proved fi ve days after the end of immunoglobulin therapy, 
but facial paresis did not recovered.
As a conclusion, the present case indicates that EBV in-
fection that causes IM must be considered among the pos-
sible causes in patients with GBS.
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